Accessibility Menu
Biodexa Pharmaceuticals Plc logo

Biodexa Pharmaceuticals Plc

(NASDAQ) BDRX

Current Price$2.14
Market Cap$962.00KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-100%
5 Year-100%
1 Year-95%
1 Month-29%
Biodexa Pharmaceuticals Plc last closing stock price
MetricPriceDate
Last closeUSD 2.132026-07-16
Biodexa Pharmaceuticals Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-17.76%USD 2.592026-07-09
1 month-28.52%USD 2.982026-06-16
3 month-38.79%USD 3.482026-04-17
Year to date-81.23%USD 11.352025-12-31
1 year-94.92%USD 41.902025-07-16
3 year-99.96%USD 6,075.002023-07-17
5 year-100%USD 3,640,000.002021-07-16
Since inception-100%USD 628,000,000.002015-12-08

Biodexa Pharmaceuticals Plc Financials at a Glance

Market Cap

$962.00KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£0.00

Net Income (TTM)

-£12.10M

EPS (TTM)

-$103.95

P/E Ratio

-0.02

Dividend

$0.00

Beta (Volatility)

1.07 (Average)

Price

$2.14

Volume

536

Open

$2.20

Previous Close

$2.14

Daily Range

$2.14 - $2.22

52-Week Range

$2.10 - $59.40

Estimated Earnings Date

Sep 11, 2026

BDRX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Biodexa Pharmaceuticals Plc

Biodexa Pharmaceuticals Plc is a biopharmaceutical company focused on developing innovative therapies to address significant unmet medical needs. Founded in 2000 and headquartered in Cardiff, UK, the company is advancing a diverse portfolio of products, including drug candidates for Type 1 diabetes and rare brain cancers.

Products and Services
  • Primary drug candidate Tolimidone for Type 1 diabetes
  • MTX110 targeting challenging brain malignancies
  • Advanced drug delivery platforms like Q-Sphera and MidaSolve
Growth Outlook
  • Ongoing Phase II trials for Tolimidone show promise in diabetes management
  • Strategic collaborations with Janssen and Melior enhance development capabilities
  • Focus on rare cancers positions Biodexa in a niche market with high demand
Financial Highlights
  • Recent quarterly revenue of 83,000 reflects early-stage product development
  • Cash and cash equivalents reached 8.5 million, supporting ongoing R&D efforts
  • Current ratio of 2.03 indicates strong liquidity for operational needs
Biodexa Pharmaceuticals is positioned in the biotechnology sector, focusing on innovative solutions for critical health challenges. The company's commitment to research and development is evident in its diverse pipeline, which includes therapies for Type 1 diabetes and various rare cancers. The strategic partnerships with established pharmaceutical companies further bolster its potential for growth and market penetration. Recent financial data indicates a solid liquidity position, allowing for continued investment in product development. As the company progresses through clinical trials, it remains a noteworthy entity in the biopharmaceutical landscape.
AI Generated • Jun 23, 2026

Industry

Biotechnology

Sector

Health Care

Employees

11

CEO

Stephen Anthony Stamp

Website

www.biodexapharma.com

Headquarters

Cardiff, WA CF10 4DQ, GB

BDRX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-55.81%

Return on Capital

-72.24%

Return on Assets

-35.09%

Earnings Yield

-50.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$962.00KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

451.60K

Volume

536

Avg. Volume

400.74K

Financials (TTM)

Gross Profit

-£7.15M

Operating Income

-£17.94M

EBITDA

-£16.80M

Operating Cash Flow

-£17.89M

Capital Expenditure

-£776.06K

Free Cash Flow

-£18.67M

Cash & ST Invst.

£8.52M

Total Debt

£60.89K

Biodexa Pharmaceuticals Plc Performance Analysis

Biodexa Pharmaceuticals Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31GBP 861,0148.3%
20232023-12-31GBP 473,603-45.0%
20242024-12-31GBP 0N/A
20252025-12-31GBP 0N/A
Biodexa Pharmaceuticals Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-100.0%
Q42024-12-31N/A
Q22025-06-30N/A
Q42025-12-31N/A
Biodexa Pharmaceuticals Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31GBP -954,136.932.3%
20232023-12-31GBP -13,928.40-98.5%
20242024-12-31GBP -741.13-94.7%
20252025-12-31GBP -79.07-89.3%
Biodexa Pharmaceuticals Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3065.4%
Q42024-12-3163.6%
Q22025-06-3058.1%
Q42025-12-3189.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

£0.00

-100.0%

Gross Profit

-£48.70K

+97.8%

Gross Margin

0.00%

N/A

Market Cap

$962.00KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$87.45K

N/A

Employees

11

N/A

Net Income

-£2.56M

+27.0%

EBITDA

-£4.68M

-104.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

£8.52M

+42.7%

Total Debt

£60.89K

-86.9%

Accounts Receivable

£221.61K

-68.5%

Inventory

£0.00

N/A

Long Term Debt

£0.00

-100.0%

Short Term Debt

£121.89K

-27.9%

Return on Assets

-35.09%

N/A

Return on Invested Capital

-72.66%

N/A

Free Cash Flow

-£2.33M

+21.6%

Operating Cash Flow

-£2.33M

+21.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GNPXGenprex, Inc.
$8.00-25.92%
GRIGRI Bio, Inc.
$1.54-4.94%
JAGXJaguar Health, Inc.
$1.34-31.54%
CNSPCNS Pharmaceuticals, Inc.
$4.74+1.28%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.36-0.08%
NVDANvidia
$207.33-0.02%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$27.51-0.12%
INTCIntel
$96.83-0.06%

Questions About BDRX

What is the current price of Biodexa Pharmaceuticals Plc?

Biodexa Pharmaceuticals Plc is trading at $2.14 per share.

What is the 52-week range for Biodexa Pharmaceuticals Plc?

Over the past 52 weeks, Biodexa Pharmaceuticals Plc has traded between $2.10 and $59.40.

How much debt does Biodexa Pharmaceuticals Plc have?

As of the most recent reporting period, Biodexa Pharmaceuticals Plc reported total debt of £82.05K.

How much cash does Biodexa Pharmaceuticals Plc have on hand?

Biodexa Pharmaceuticals Plc reported £11.48M in cash and cash equivalents in its most recent financial results.

What is Biodexa Pharmaceuticals Plc’s dividend yield?

Biodexa Pharmaceuticals Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services